|
 
- 现金
- 2481 元
- 精华
- 5
- 帖子
- 855
- 注册时间
- 2002-3-30
- 最后登录
- 2012-7-8
|
1楼
发表于 2003-3-26 19:06
HBV Patients with Diverse Baseline Characteristics
Abstract Summary
Hepsera (adefovir dipivoxil/ADV) is a nucleotide analogue with in vivo and in vitro activity against wild type and Epivir-HBV- (lamivudine)-resistant (LAM-R) hepatitis B virus (HBV). The objective of the current study was to compare the efficacy of ADV 10mg over 48 weeks in a broad range of CHB patient populations.
Serum HBV DNA (Roche Amplicor, LLQ 400 copies/mL) and ALT were evaluated in 692 patients with CHB receiving ADV 10mg in 5 studies.
The results are summarized in the table below.
Conclusions: ADV 10mg once-daily resulted in consistent antiviral and biochemical response in HBeAg positive and negative patients with CHB, including LAM-R HBV, HIV/HBV coinfection, compensated and decompensated liver function and in the post-liver transplantation setting.
[upload=gif]uploadImages/2003326534474490.gif[/upload]
03/24/03
Reference
P Marcellin and others. ADEFOVIR DIPIVOXIL 10 MG (ADV) RESULTS IN CONSISTENT EFFICACY IN CHRONIC HEPATITIS B (CHB) PATIENTS WITH DIVERSE BASELINE CHARACTERISTICS. Abstract 3625.00. Abstracts of the 38th Annual Meeting of the European Association of the Study of the Liver (EASL).
|
|
